60 Percent of Patients Receiving LYNPARZA
Remained Progression-Free at Three Years Compared to 27 Percent on
Placebo Following Platinum-Based Chemotherapy
LYNPARZA Is the Only PARP Inhibitor to
Demonstrate an Improvement in Progression-Free Survival in
First-Line Maintenance Treatment for Newly-Diagnosed, Advanced
Ovarian Cancer
AstraZeneca and Merck (NYSE:MRK), known as MSD outside the
United States and Canada, today announced detailed results from the
Phase 3 SOLO-1 trial testing LYNPARZA 300 mg tablets twice daily as
a maintenance treatment for patients with newly-diagnosed advanced
BRCA-mutated (BRCAm) ovarian cancer who were in complete or partial
response following first-line standard platinum-based
chemotherapy.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20181021005027/en/
(Graphic: Business Wire)
Results of the trial confirm the statistically-significant and
clinically-meaningful improvement in progression-free survival
(PFS) for LYNPARZA as compared to placebo, reducing the risk of
disease progression or death by 70 percent (HR=0.30 [95% CI,
0.23-0.41]; p<0.001). At 41 months of follow-up, the median PFS
for patients treated with LYNPARZA was not reached compared to 13.8
months for patients treated with placebo. Of those receiving
LYNPARZA, 60.4 percent remained progression-free at 36 months,
compared to 26.9 percent of women in the placebo arm. The data were
presented at the Presidential Symposium of the ESMO 2018 Congress
in Munich, Germany and published simultaneously online in the New
England Journal of Medicine (NEJM).
Summary of PFS as Assessed by Investigators1,2
LYNPARZA
(n=260)
Placebo (n=131) Number of patients with event
(%)3 102 (39.2) 96 (73.3)
Median (in months) Not reached
13.8 Hazard ratio (95% CI) 0.30
(0.23-0.41) P-value p<0.001 1
Investigator-assessed 2 Median (interquartile range) duration of
follow-up 40.7 months (34.9–42.9) for LYNPARZA and 41.2 months
(32.2–41.6) for placebo 3 Analysis was done at 50.6 percent
maturity
Sean Bohen, executive vice president, Global Medicines
Development and chief medical officer at AstraZeneca, said, “There
is currently a significant unmet need in the treatment of advanced
ovarian cancer because 70 percent of women relapse within the first
three years after their initial treatment. The remarkable results
of the SOLO-1 trial, which showed that 60 percent of women with
newly-diagnosed, advanced BRCA-mutated ovarian cancer remained
progression-free at three years, highlight the potential of
LYNPARZA as a first-line maintenance therapy in this setting.”
Dr. Roy Baynes, senior vice president and head of Global
Clinical Development, chief medical officer, Merck Research
Laboratories, said, “Our collective goal in oncology research is to
improve long-term outcomes for people living with cancer. Based on
the SOLO-1 trial results, LYNPARZA is the only PARP inhibitor to
have demonstrated a significant and clinically-meaningful
improvement in reducing the risk of progression or death for
newly-diagnosed patients with advanced BRCA-mutated ovarian cancer
following platinum-based chemotherapy. We are working with
regulatory authorities as quickly as possible to seek approval of
LYNPARZA for these patients.”
Kathleen Moore, co-principal investigator of the SOLO-1 trial
and associate director, Stephenson Cancer Center at The University
of Oklahoma, Oklahoma City, Oklahoma, said, “Women with ovarian
cancer are often diagnosed with advanced disease, which
unfortunately is associated with poor long-term survival rates. The
newly-diagnosed setting is our best opportunity to achieve a
sustained remission, since once a patient’s ovarian cancer recurs,
it is typically incurable. The SOLO-1 results demonstrate the
potential of LYNPARZA maintenance therapy earlier in the treatment
pathway and reinforce the importance of identifying a patient’s
BRCA mutation status at the time of diagnosis – these results could
change the way we treat women with advanced BRCA-mutated ovarian
cancer.”
The SOLO-1 safety profile was in line with that observed in
prior clinical trials. The most common adverse events (AEs) ≥ 20
percent were nausea (77%), fatigue (64%), vomiting (40%), anemia
(39%) and diarrhea (34%). The most common ≥ Grade 3 AEs were anemia
(22%) and neutropenia (8%). Seventy-one percent of patients on
LYNPARZA remained on the recommended starting dose. Additionally,
88 percent of patients on LYNPARZA continued treatment without an
AE-related discontinuation. Further, 48 percent of patients on
LYNPARZA did not have a dose interruption as a result of an AE.
Per SOLO-1 protocol guidelines, patients who demonstrated a
complete response (no radiological evidence of disease) at two
years stopped treatment with LYNPARZA; patients who demonstrated a
partial response and, who in the opinion of the treating physician
can derive further benefit from continuous treatment, were treated
beyond two years.
AstraZeneca and Merck are exploring additional trials in ovarian
cancer, including the ongoing GINECO/ENGOTov25 Phase 3 trial,
PAOLA-1. This trial is testing the effect of LYNPARZA in
combination with bevacizumab as a maintenance treatment for
patients with newly-diagnosed advanced ovarian cancer regardless of
their BRCA status. Results are expected during the second half of
2019.
LYNPARZA is a first-in-class poly ADP-ribose polymerase (PARP)
inhibitor approved in the U.S. since 2014. LYNPARZA has a broad
clinical development program and AstraZeneca and Merck are working
together to deliver LYNPARZA as quickly as possible to more
patients across multiple cancer types.
LYNPARZA is not currently FDA-approved for advanced BRCAm
ovarian cancer treatment in the first-line maintenance setting.
LYNPARZA is indicated for the maintenance treatment of recurrent
ovarian cancer in response to platinum-based chemotherapy
regardless of BRCA mutation status, and for the treatment of
advanced ovarian cancer patients with a germline BRCA mutation
previously treated with three or more lines of chemotherapy.
Physicians should select advanced ovarian cancer patients for
therapy based on a FDA-approved companion diagnostic. Please see
complete indications below.
Important Safety Information
Contraindications
There are no contraindications for LYNPARZA.
Warnings and Precautions
Myelodysplastic Syndrome/Acute Myeloid Leukemia
(MDS/AML): Occurred in <1.5% of patients exposed to LYNPARZA
monotherapy, and the majority of events had a fatal outcome. The
duration of therapy in patients who developed secondary MDS/AML
varied from <6 months to >2 years. All of these patients had
previous chemotherapy with platinum agents and/or other
DNA-damaging agents, including radiotherapy, and some also had a
history of more than one primary malignancy or of bone marrow
dysplasia.
Do not start LYNPARZA until patients have recovered from
hematological toxicity caused by previous chemotherapy (≤Grade 1).
Monitor complete blood count for cytopenia at baseline and monthly
thereafter for clinically significant changes during treatment. For
prolonged hematological toxicities, interrupt LYNPARZA and monitor
blood count weekly until recovery.
If the levels have not recovered to Grade 1 or less after 4
weeks, refer the patient to a hematologist for further
investigations, including bone marrow analysis and blood sample for
cytogenetics. Discontinue LYNPARZA if MDS/AML is confirmed.
Pneumonitis: Occurred in <1% of patients exposed to
LYNPARZA, and some cases were fatal. If patients present with new
or worsening respiratory symptoms such as dyspnea, cough, and
fever, or a radiological abnormality occurs, interrupt LYNPARZA
treatment and initiate prompt investigation. Discontinue LYNPARZA
if pneumonitis is confirmed and treat patient appropriately.
Embryo-Fetal Toxicity: Based on its mechanism of action
and findings in animals,
LYNPARZA can cause fetal harm. A pregnancy test is recommended
for females of
reproductive potential prior to initiating treatment.
Females
Advise females of reproductive potential of the potential risk
to a fetus and to use effective contraception during treatment and
for 6 months following the last dose.
Males
Advise male patients with female partners of reproductive
potential or who are pregnant to use effective contraception during
treatment and for 3 months following the last dose of LYNPARZA and
to not donate sperm during this time.
Adverse Reactions—Maintenance Setting
Most common adverse reactions (Grades 1-4) in ≥20% of patients
in clinical trials of LYNPARZA in the maintenance setting for
SOLO-2: nausea (76%), fatigue (including asthenia) (66%), anemia
(44%), vomiting (37%), nasopharyngitis/upper respiratory tract
infection (URI)/influenza (36%), diarrhea (33%), arthralgia/myalgia
(30%), dysgeusia (27%), headache (26%), decreased appetite (22%),
and stomatitis (20%).
Study 19: nausea (71%), fatigue (including asthenia) (63%),
vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract
infection (22%), constipation (22%), headache (21%), and decreased
appetite (21%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of
patients in clinical trials of LYNPARZA in the maintenance setting
(SOLO-2/Study 19) were: increase in mean corpuscular volume
(89%/82%), decrease in hemoglobin (83%/82%), decrease in leukocytes
(69%/58%), decrease in lymphocytes (67%/52%), decrease in absolute
neutrophil count (51%/47%), increase in serum creatinine (44%/45%),
and decrease in platelets (42%/36%).
Adverse Reactions—Advanced gBRCAm Ovarian Cancer
Most common adverse reactions (Grades 1-4) in ≥20% of patients
in clinical trials of LYNPARZA for advanced gBRCAm ovarian cancer
after 3 or more lines of chemotherapy (pooled from 6 studies) were:
fatigue (including asthenia) (66%), nausea (64%), vomiting (43%),
anemia (34%), diarrhea (31%), nasopharyngitis/upper respiratory
tract infection (URI) (26%), dyspepsia (25%), myalgia (22%),
decreased appetite (22%), and arthralgia/musculoskeletal pain
(21%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of
patients in clinical trials of LYNPARZA for advanced gBRCAm ovarian
cancer (pooled from 6 studies) were: decrease in hemoglobin (90%),
increase in mean corpuscular volume (57%), decrease in lymphocytes
(56%), increase in serum creatinine (30%), decrease in platelets
(30%), and decrease in absolute neutrophil count (25%).
Adverse Reactions—gBRCAm, HER2-Negative Breast Cancer
Most common adverse reactions (Grades 1-4) in ≥20% of patients
in OlympiAD were: nausea (58%), anemia (40%), fatigue (including
asthenia) (37%), vomiting (30%), neutropenia (27%), respiratory
tract infection (27%), leukopenia (25%), diarrhea (21%), and
headache (20%).
Most common laboratory abnormalities (Grades 1-4) in >25% of
patients in OlympiAD were: decrease in hemoglobin (82%), decrease
in lymphocytes (73%), decrease in leukocytes (71%), increase in
mean corpuscular volume (71%), decrease in absolute neutrophil
count (46%), and decrease in platelets (33%).
Drug Interactions
Anticancer Agents: Clinical studies of LYNPARZA in
combination with other myelosuppressive anticancer agents,
including DNA-damaging agents, indicate a potentiation and
prolongation of myelosuppressive toxicity.
CYP3A Inhibitors: Avoid concomitant use of strong or
moderate CYP3A inhibitors. If a strong or moderate CYP3A inhibitor
must be co-administered, reduce the dose of LYNPARZA. Advise
patients to avoid grapefruit, grapefruit juice, Seville oranges,
and Seville orange juice during LYNPARZA treatment.
CYP3A Inducers: Avoid concomitant use of strong or
moderate CYP3A inducers when using LYNPARZA. If a moderate inducer
cannot be avoided, there is a potential for decreased efficacy of
LYNPARZA.
Use In Specific Populations
Lactation: No data are available regarding the presence
of olaparib in human milk, its effects on the breastfed infant or
on milk production. Because of the potential for serious adverse
reactions in the breastfed infant, advise a lactating woman not to
breastfeed during treatment with LYNPARZA and for 1 month after
receiving the final dose.
Pediatric Use: The safety and efficacy of LYNPARZA have
not been established in pediatric patients.
Hepatic Impairment: No adjustment to the starting dose is
required in patients with mild hepatic impairment (Child-Pugh
classification A). There are no data in patients with moderate or
severe hepatic impairment.
Renal Impairment: No adjustment to the starting dose is
necessary in patients with mild renal impairment (CLcr=51-80
mL/min). In patients with moderate renal impairment (CLcr=31-50
mL/min), reduce the dose to 200 mg twice daily. There are no data
in patients with severe renal impairment or end-stage renal disease
(CLcr ≤30 mL/min).
Indications
LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor
indicated:
For the maintenance treatment of adult patients with recurrent
epithelial ovarian, fallopian tube, or primary peritoneal cancer,
who are in complete or partial response to platinum-based
chemotherapy.
For the treatment of adult patients with deleterious or
suspected deleterious germline BRCA-mutated (gBRCAm) advanced
ovarian cancer who have been treated with 3 or more prior lines of
chemotherapy. Select patients for therapy based on an FDA-approved
companion diagnostic for LYNPARZA.
In patients with deleterious or suspected deleterious gBRCAm,
human epidermal growth factor receptor 2 (HER2)-negative metastatic
breast cancer who have previously been treated with chemotherapy in
the neoadjuvant, adjuvant or metastatic setting. Patients with
hormone receptor (HR)-positive breast cancer should have been
treated with a prior endocrine therapy or be considered
inappropriate for endocrine treatment. Select patients for therapy
based on an FDA-approved companion diagnostic for LYNPARZA.
Please see complete Prescribing Information,
including Patient Information (Medication Guide).
About the SOLO-1 Phase 3 Trial
SOLO-1 is a Phase 3, randomized, double-blind,
placebo-controlled, multi-center trial to evaluate the efficacy and
safety of LYNPARZA tablets (300 mg twice daily) as maintenance
monotherapy compared with placebo in newly-diagnosed patients with
advanced BRCA-mutated ovarian cancer following platinum-based
chemotherapy. The trial randomized 391 patients with a deleterious
or suspected deleterious BRCA1 or BRCA2 mutation who were in
clinical complete or partial response following platinum-based
chemotherapy. Patients were randomized (2:1) to receive LYNPARZA or
placebo for up to two years or until disease progression (at the
investigator’s discretion). The primary endpoint was
investigator-assessed progression-free survival and key secondary
endpoints include time to second disease progression or death, time
to first subsequent treatment and overall survival.
About Ovarian Cancer
Approximately 20,000 women in the U.S. are diagnosed with
ovarian cancer (including ovarian, fallopian tube and primary
peritoneal cancers) each year. Among women in the U.S., it is the
ninth most common cancer and the fifth leading cause of cancer
death.
The risk of developing ovarian cancer is increased in women with
specific inherited genetic abnormalities, including BRCA
mutations.
About BRCA Mutations
BRCA1 and BRCA2 are human genes that produce proteins
responsible for repairing damaged DNA and play an important role in
maintaining the genetic stability of cells. When either of these
genes is mutated, or altered, such that its protein product either
is not made or does not function correctly, DNA damage may not be
repaired properly, and cells become unstable. As a result, cells
are more likely to develop additional genetic alterations that can
lead to cancer.
About LYNPARZA® (olaparib)
LYNPARZA is the first-in-class PARP inhibitor and the first
targeted treatment to potentially exploit DNA damage response (DDR)
pathway deficiencies, such as BRCA mutations, to
preferentially kill cancer cells. Specifically, in vitro studies
have shown that LYNPARZA-induced cytotoxicity may involve
inhibition of PARP enzymatic activity and increased formation of
PARP-DNA complexes, resulting in DNA damage and cancer cell death.
LYNPARZA is being tested in a range of DDR-deficient tumor
types.
LYNPARZA, which is being jointly developed and commercialized by
AstraZeneca and Merck, has a broad and advanced clinical trial
development program, and AstraZeneca and Merck are working together
to deliver it as quickly as possible to more patients across
multiple cancer types.
About the AstraZeneca and Merck Strategic Oncology
Collaboration
In July 2017, AstraZeneca and Merck, known as MSD outside the
United States and Canada, announced a global strategic oncology
collaboration to co-develop and co-commercialize LYNPARZA, the
world’s first PARP inhibitor, and potential new medicine
selumetinib, a MEK inhibitor, for multiple cancer types. Working
together, the companies will develop LYNPARZA and selumetinib in
combination with other potential new medicines and as
monotherapies. Independently, the companies will develop LYNPARZA
and selumetinib in combination with their respective PD-L1 and PD-1
medicines.
Merck’s Focus on Cancer
Our goal is to translate breakthrough science into innovative
oncology medicines to help people with cancer worldwide. At Merck,
the potential to bring new hope to people with cancer drives our
purpose and supporting accessibility to our cancer medicines is our
commitment.
As part of our focus on cancer, Merck is committed to exploring
the potential of immuno-oncology with one of the largest
development programs in the industry across more than 30 tumor
types. We also continue to strengthen our portfolio through
strategic acquisitions and are prioritizing the development of
several promising oncology candidates with the potential to improve
the treatment of advanced cancers.
For more information about our oncology clinical trials, visit
www.merck.com/clinicaltrials.
About Merck
For more than a century, Merck, a leading global
biopharmaceutical company known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases.
Through our prescription medicines, vaccines, biologic therapies
and animal health products, we work with customers and operate in
more than 140 countries to deliver innovative health solutions. We
also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships. Today,
Merck continues to be at the forefront of research to advance the
prevention and treatment of diseases that threaten people and
communities around the world - including cancer, cardio-metabolic
diseases, emerging animal diseases, Alzheimer’s disease and
infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect with us
on Twitter, Facebook, Instagram, YouTube
and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2017
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181021005027/en/
MerckMediaPamela Eisele, 267-305-3558orMichael Close,
267-305-1211orInvestorsTeri Loxam, 908-740-1986orMichael DeCarbo,
908-740-1807
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024